Cabozantinib

Overview

Cabozantinib is a small molecule kinase inhibitor that targets multiple tyrosine kinases, including VEGFR2 and MET. It is primarily utilized in the treatment of medullary thyroid cancer and renal cell carcinoma.

API suppliers (1)

Suppliers of Cabozantinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MSN Laboratories Private LimitedIndia2 active DMF

Therapeutic areas